ABT vs. GH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ABT and GH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ABT’s market capitalization of 233.90 billion USD is substantially larger than GH’s 6.26 billion USD, indicating a significant difference in their market valuations.
GH carries a higher beta at 1.38, indicating it’s more sensitive to market moves, while ABT (beta: 0.74) exhibits greater stability.
| Symbol | ABT | GH |
|---|---|---|
| Company Name | Abbott Laboratories | Guardant Health, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Medical - Diagnostics & Research |
| CEO | Robert B. Ford | Helmy Eltoukhy |
| Price | 134.44 USD | 50.5 USD |
| Market Cap | 233.90 billion USD | 6.26 billion USD |
| Beta | 0.74 | 1.38 |
| Exchange | NYSE | NASDAQ |
| IPO Date | March 17, 1980 | October 4, 2018 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ABT and GH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ABT
30.76%
Medical - Devices Industry
- Max
- 49.04%
- Q3
- 9.53%
- Median
- -7.46%
- Q1
- -32.83%
- Min
- -82.64%
In the upper quartile for the Medical - Devices industry, ABT’s Return on Equity of 30.76% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
GH
368.51%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
GH’s Return on Equity of 368.51% is exceptionally high, placing it well beyond the typical range for the Medical - Diagnostics & Research industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Return on Invested Capital
ABT
19.13%
Medical - Devices Industry
- Max
- 21.88%
- Q3
- 6.63%
- Median
- -1.11%
- Q1
- -21.08%
- Min
- -51.95%
In the upper quartile for the Medical - Devices industry, ABT’s Return on Invested Capital of 19.13% signifies a highly effective use of its capital to generate profits when compared to its peers.
GH
-40.79%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
GH has a negative Return on Invested Capital of -40.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
Net Profit Margin
ABT
31.89%
Medical - Devices Industry
- Max
- 44.80%
- Q3
- 9.77%
- Median
- -5.53%
- Q1
- -29.37%
- Min
- -87.68%
A Net Profit Margin of 31.89% places ABT in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.
GH
-53.82%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
GH has a negative Net Profit Margin of -53.82%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin
ABT
16.97%
Medical - Devices Industry
- Max
- 30.13%
- Q3
- 13.12%
- Median
- 3.47%
- Q1
- -24.42%
- Min
- -80.56%
An Operating Profit Margin of 16.97% places ABT in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
GH
-58.78%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
GH has a negative Operating Profit Margin of -58.78%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | ABT | GH |
|---|---|---|
| Return on Equity (TTM) | 30.76% | 368.51% |
| Return on Assets (TTM) | 16.58% | -30.99% |
| Return on Invested Capital (TTM) | 19.13% | -40.79% |
| Net Profit Margin (TTM) | 31.89% | -53.82% |
| Operating Profit Margin (TTM) | 16.97% | -58.78% |
| Gross Profit Margin (TTM) | 55.89% | 61.34% |
Financial Strength
Current Ratio
ABT
1.78
Medical - Devices Industry
- Max
- 12.68
- Q3
- 6.30
- Median
- 4.05
- Q1
- 1.85
- Min
- 0.01
ABT’s Current Ratio of 1.78 falls into the lower quartile for the Medical - Devices industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
GH
4.11
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
GH’s Current Ratio of 4.11 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ABT
0.27
Medical - Devices Industry
- Max
- 2.34
- Q3
- 1.09
- Median
- 0.37
- Q1
- 0.08
- Min
- 0.00
ABT’s Debt-to-Equity Ratio of 0.27 is typical for the Medical - Devices industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
GH
-5.21
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
GH has a Debt-to-Equity Ratio of -5.21, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
Interest Coverage Ratio
ABT
15.39
Medical - Devices Industry
- Max
- 18.18
- Q3
- 7.53
- Median
- 0.85
- Q1
- -9.80
- Min
- -33.94
ABT’s Interest Coverage Ratio of 15.39 is in the upper quartile for the Medical - Devices industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
GH
-166.83
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
GH has a negative Interest Coverage Ratio of -166.83. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | ABT | GH |
|---|---|---|
| Current Ratio (TTM) | 1.78 | 4.11 |
| Quick Ratio (TTM) | 1.27 | 3.76 |
| Debt-to-Equity Ratio (TTM) | 0.27 | -5.21 |
| Debt-to-Asset Ratio (TTM) | 0.16 | 0.97 |
| Net Debt-to-EBITDA Ratio (TTM) | 0.60 | -1.53 |
| Interest Coverage Ratio (TTM) | 15.39 | -166.83 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ABT and GH. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ABT
1.70%
Medical - Devices Industry
- Max
- 3.57%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 1.70%, ABT offers a more attractive income stream than most of its peers in the Medical - Devices industry, signaling a strong commitment to shareholder returns.
GH
0.00%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ABT
28.92%
Medical - Devices Industry
- Max
- 102.12%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ABT’s Dividend Payout Ratio of 28.92% is in the upper quartile for the Medical - Devices industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
GH
0.00%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ABT | GH |
|---|---|---|
| Dividend Yield (TTM) | 1.70% | 0.00% |
| Dividend Payout Ratio (TTM) | 28.92% | 0.00% |
Valuation
Price-to-Earnings Ratio
ABT
17.40
Medical - Devices Industry
- Max
- 90.56
- Q3
- 56.92
- Median
- 43.19
- Q1
- 21.79
- Min
- 5.55
In the lower quartile for the Medical - Devices industry, ABT’s P/E Ratio of 17.40 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
GH
-15.02
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
GH has a negative P/E Ratio of -15.02. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
Forward P/E to Growth Ratio
ABT
1.73
Medical - Devices Industry
- Max
- 6.56
- Q3
- 3.52
- Median
- 2.22
- Q1
- 0.55
- Min
- 0.03
ABT’s Forward PEG Ratio of 1.73 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
GH
0.63
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
GH’s Forward PEG Ratio of 0.63 is within the middle range of its peers in the Medical - Diagnostics & Research industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ABT
5.52
Medical - Devices Industry
- Max
- 15.74
- Q3
- 8.12
- Median
- 3.40
- Q1
- 2.37
- Min
- 0.42
ABT’s P/S Ratio of 5.52 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
GH
8.08
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
GH’s P/S Ratio of 8.08 is in the upper echelon for the Medical - Diagnostics & Research industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio
ABT
4.81
Medical - Devices Industry
- Max
- 16.65
- Q3
- 8.03
- Median
- 3.73
- Q1
- 1.92
- Min
- 0.65
ABT’s P/B Ratio of 4.81 is within the conventional range for the Medical - Devices industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
GH
-24.94
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
Valuation at a Glance
| Symbol | ABT | GH |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 17.40 | -15.02 |
| Forward PEG Ratio (TTM) | 1.73 | 0.63 |
| Price-to-Sales Ratio (P/S, TTM) | 5.52 | 8.08 |
| Price-to-Book Ratio (P/B, TTM) | 4.81 | -24.94 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 35.14 | -20.52 |
| EV-to-EBITDA (TTM) | 21.49 | -17.25 |
| EV-to-Sales (TTM) | 5.68 | 8.87 |